Le Lézard
Classified in: Health, Business
Subject: FNC

Haemonetics Completes Debt Refinancing With Five-Year Senior Unsecured Credit Facilities


BRAINTREE, Mass., June 18, 2018 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company has entered into a new $700 million credit agreement with its lenders, comprised of a $350 million senior unsecured term loan A and a $350 million senior unsecured revolving credit facility, both due 2023. The Company has used initial proceeds from the new credit agreement to repay its $254 million senior unsecured term loan A due June 2019.

HAE logo April 2016.

Chris Simon, President and CEO, stated: "Our new credit agreement enhances our strong financial profile and eases certain covenants, providing increased flexibility in a variety of areas, including expanded options for permitted debt and investments. Funds from these facilities combined with our strong cash flow enhance our ability to execute on our growth plans."

Borrowings under the new credit facilities initially bear interest at an annual rate of LIBOR plus 1.25%, which may change based on the Company's leverage ratio. The revolving credit facility carries an unused fee of 0.175% annually, which may change based on the Company's leverage ratio.

JPMorgan Chase Bank, N.A., Citibank, N.A. and Citizens Bank, N.A. are co-lead arrangers and co-bookrunners for the new term loans, leading a syndicate that includes five other banks.

ABOUT HAEMONETICS
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

FORWARD LOOKING STATEMENTS
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding the Company's growth initiatives, improved liquidity and financial flexibility, and related expectations. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, our ability to continue to satisfy our covenants and agreements under the new credit agreement and other indebtedness and to otherwise comply with our payment obligations. These and other factors are identified and described in more detail in the Company's periodic reports and other filings with the SEC. The Company does not undertake to update these forward-looking statements.

 

Investor Contact

Media Contact

Gerry Gould, VP-Investor Relations 

Carla Burigatto, VP-Communications

(781) 356-9402

(781) 348-7263

[email protected]

[email protected]

 

 

SOURCE Haemonetics Corporation


These press releases may also interest you

at 18:30
Striking Teamsters at pharmaceutical giant Cencora (formerly known as AmerisourceBergen) rallied today outside the company's Sacramento distribution center. The 124 warehouse workers are members of Teamsters Local 150 and have been on strike since...

at 18:00
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Jessica M. Konen's Lab at Emory University School of Medicine....

at 17:58
More than 200 workers at American Medical Response (AMR) in Springfield and Greenfield have voted overwhelmingly to join Teamsters Local 404....

at 17:54
The American Association of Kidney Patients (AAKP), the largest and oldest independent kidney patient organization in the nation, is celebrating National Doctors Day by highlighting three top kidney medical experts and authors known for their...

at 17:20
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024. One individual was...

at 17:15
Paladin Labs Inc., a subsidiary of Endo International plc , today announced Health Canada's approval of WAKIX® (pitolisant hydrochloride tablets) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in pediatric patients aged 6 years...



News published on and distributed by: